D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69.
The D2 dopamine receptor agonist bromocriptine has been used clinically for reducing tumor mass of pituitary adenomas arising from lactotroph origins. As well, bromocriptine has been shown to have an antiproliferative effect on primary lactotrophs and lactotroph-derived cell lines. The presence of D2 dopamine-like receptors on NCI-H69 cells was previously established by the use of [(125)I]iodosulpride binding and has been confirmed in this study by use of reverse transcription PCR with receptor-specific primers. The reverse transcription PCR analysis of NCI-H69 cells demonstrates that both the D2s and D2l are expressed in NCI-H69 cells, with D2s having the higher relative expression. The activation of the D2R results in an inhibition of growth of NCI-H69 cells as assessed by the incorporation of [(3)H]thymidine; a process not sensitive to pertussis toxin. In NCI-H69 cells, the D2 dopamine-like receptor is coupled to the inhibition of forskolin-stimulated cAMP accumulation and to the stimulation of phospholipase D. The receptor-mediated inhibition of cAMP accumulation is ablated by overnight treatment with pertussis toxin but the stimulation of phospholipase D mediated by dopaminergic agonists is not. These data suggest that the phospholipase D pathway is responsible for the antiproliferative effects of D2 dopamine-like receptors agonists in small cell lung cancer cells. In support of this hypothesis, the inhibition of [(3)H]thymidine incorporation mediated by dopaminergic agonists was shown to be sensitive to the presence of ethanol. Taken together, these data suggest that the D2 dopamine-like receptor activates phospholipase D, which ultimately leads to an inhibition of growth of this small cell lung cancer cell line.